Expanding the clinical development of oral epetraborole into a Phase 2 proof-of-concept clinical study in adults with phlebotomy-dependent polycythemia vera (PV), supported by robust preclinical and clinical enabling data showing consistent hematocrit reductions.

Expected impact: Establishes a novel mechanism of action treatment option for PV, potentially addressing a market of approximately 155,000 affected individuals in the U.S.

Developing oral AN2-502998, an investigational boron-based small molecule, for the treatment of chronic Chagas disease. Dosing has been completed in the Phase 1 first-in-human trial.

Expected impact: Provides a potential first-in-class oral treatment for adults with chronic Chagas disease, addressing a major global health unmet need.

Advancing the newly declared ENPP1 small molecule candidate for the treatment of solid tumors from early research into development.

Expected impact: Broadens the company's boron chemistry platform into oncology, diversifying the pipeline beyond infectious and hematologic diseases.